Thikhamporn Tawantanakorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thikhamporn Tawantanakorn has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Chainarong Phalanusitthepha
Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Tharathorn Suwatthanarak
Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Thawatchai Akaraviputh
Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Vitoon Chinswangwatanakul
Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Asada Methasate
Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Atthaphorn Trakarnsanga
Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2 shared publications
Latest Publications
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features
PURPOSE: National guidelines recommend colorectal resection when pathology from a malignant colorectal polyp reveals high-risk features (HRFs). However, some patients opt to avoid surgery because of concerns about associated morbidity and potential impacts on quality of life, despite the risk of residual disease. METHODS: In this single-center cohort study of patients treated between 2015 and 2022, we retrospectively compared rates of residual disease between patients who underwent immediate surgery and patients managed nonoperatively after removal of a malignant polyp with HRFs. RESULTS: Of 336 patients who underwent a polypectomy in the colon (n = 226) or rectum (n = 110) and had at least one HRF, 208 (62%) underwent immediate surgery and 128 (38%) were managed nonoperatively. Residual disease was identified in 63 patients (19%), either at the time of immediate surgery or during surveillance in the nonoperative group. In the immediate surgery group, 51 (25%) patients had residual disease, including 19 (9%) with residual disease in the bowel wall and 39 (19%) in locoregional lymph nodes (LNs). In the nonoperative cohort group, 12 (9%) developed recurrence after polypectomy during surveillance, including 7 (6%) in the bowel wall and 5 (4%) in locoregional LNs. In the nonoperative group, all recurrences after polypectomy were successfully treated with salvage surgery (n = 6) or chemoradiotherapy (n = 6). Distant metastases occurred in 2% of patients. CONCLUSION: The risk of residual disease after removal of a malignant polyp with HRFs approaches 20%. Patients who are concerned about the potential morbidity of surgery and its impact on postoperative quality of life should be counseled about this risk, as well as the availability of effective salvage treatments after nonoperative surveillance.
- Open Access
- 30 September 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (5) , 610-619
Timed barium esophagography to predict recurrent achalasia after peroral endoscopic myotomy: a retrospective study in Thailand
Background/Aims: Achalasia is a rare esophageal motility disease, for which peroral endoscopic myotomy (POEM) has emerged as a promising treatment option; however, recurrence remains a challenge. Timed barium esophagography (TBE) is a useful diagnostic tool and potential outcome predictor of achalasia. This study aimed to determine predictive tools for recurrence after POEM.Methods: This retrospective study enrolled achalasia patients who underwent POEM between January 2015 and December 2021. Patients were categorized into two groups using the 1-month post-POEM Eckardt scores and TBE: the discordant group (Eckardt score improved >50%, TBE decreased 50%). Recurrence was defined as a reincrease in the Eckardt score to more than three during follow-up.Results: Complete medical records were available in 30 patients who underwent POEM. Seventeen patients (56.7%) were classified into the discordant group, while 13 patients (43.3%) were in the concordant group. The overall recurrence rate was 11.9% at 1-year, increasing to 23.8% during the extended follow-up. The discordant group had a 6.87 fold higher recurrence rate than the concordant group (52.9% vs. 7.7%, p=0.017).Conclusions: These results strongly suggest that combining the Eckardt score with TBE can effectively predict recurrent achalasia after POEM. Patients in the discordant group had an elevated risk.
- 30 September 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (5) , 610-619
Open AccessTimed barium esophagography to predict recurrent achalasia after peroral endoscopic myotomy: a retrospective study in Thailand
Background/Aims: Achalasia is a rare esophageal motility disease, for which peroral endoscopic myotomy (POEM) has emerged as a promising treatment option; however, recurrence remains a challenge. Timed barium esophagography (TBE) is a useful diagnostic tool and potential outcome predictor of achalasia. This study aimed to determine predictive tools for recurrence after POEM.Methods: This retrospective study enrolled achalasia patients who underwent POEM between January 2015 and December 2021. Patients were categorized into two groups using the 1-month post-POEM Eckardt scores and TBE: the discordant group (Eckardt score improved >50%, TBE decreased 50%). Recurrence was defined as a reincrease in the Eckardt score to more than three during follow-up.Results: Complete medical records were available in 30 patients who underwent POEM. Seventeen patients (56.7%) were classified into the discordant group, while 13 patients (43.3%) were in the concordant group. The overall recurrence rate was 11.9% at 1-year, increasing to 23.8% during the extended follow-up. The discordant group had a 6.87 fold higher recurrence rate than the concordant group (52.9% vs. 7.7%, p=0.017).Conclusions: These results strongly suggest that combining the Eckardt score with TBE can effectively predict recurrent achalasia after POEM. Patients in the discordant group had an elevated risk.
- Open Access
- 30 May 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (3) , 335-341
Aerosol protection using modified N95 respirator during upper gastrointestinal endoscopy: a randomized controlled trial
Background/Aims: The coronavirus disease 2019 pandemic has affected the worldwide practice of upper gastrointestinal endoscopy. Here we designed a modified N95 respirator with a channel for endoscope insertion and evaluated its efficacy in upper gastrointestinal endoscopy.Methods: Thirty patients scheduled for upper gastrointestinal endoscopy were randomized into the modified N95 (n=15) or control (n=15) group. The mask was placed on the patient after anesthesia administration and particles were counted every minute before (baseline) and during the procedure by a TSI AeroTrak particle counter (9306-04; TSI Inc.) and categorized by size (0.3, 0.5, 1, 3, 5, and 10 µm). Differences in particle counts between time points were recorded.Results: During the procedure, the modified N95 group displayed significantly smaller overall particle sizes than the control group (median [interquartile range], 231 [54–385] vs. 579 [213–1,379]×103/m3; p=0.056). However, the intervention group had a significant decrease in 0.3-µm particles (68 [–25–185] vs. 242 [72–588]×103/m3; p=0.045). No adverse events occurred in either group. The device did not cause any inconvenience to the endoscopists or patients.Conclusions: This modified N95 respirator reduced the number of particles, especially 0.3-µm particles, generated during upper gastrointestinal endoscopy.
- 30 May 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (3) , 335-341
Open AccessAerosol protection using modified N95 respirator during upper gastrointestinal endoscopy: a randomized controlled trial
Background/Aims: The coronavirus disease 2019 pandemic has affected the worldwide practice of upper gastrointestinal endoscopy. Here we designed a modified N95 respirator with a channel for endoscope insertion and evaluated its efficacy in upper gastrointestinal endoscopy.Methods: Thirty patients scheduled for upper gastrointestinal endoscopy were randomized into the modified N95 (n=15) or control (n=15) group. The mask was placed on the patient after anesthesia administration and particles were counted every minute before (baseline) and during the procedure by a TSI AeroTrak particle counter (9306-04; TSI Inc.) and categorized by size (0.3, 0.5, 1, 3, 5, and 10 µm). Differences in particle counts between time points were recorded.Results: During the procedure, the modified N95 group displayed significantly smaller overall particle sizes than the control group (median [interquartile range], 231 [54–385] vs. 579 [213–1,379]×103/m3; p=0.056). However, the intervention group had a significant decrease in 0.3-µm particles (68 [–25–185] vs. 242 [72–588]×103/m3; p=0.045). No adverse events occurred in either group. The device did not cause any inconvenience to the endoscopists or patients.Conclusions: This modified N95 respirator reduced the number of particles, especially 0.3-µm particles, generated during upper gastrointestinal endoscopy.
- Open Access
- 24 August 2022
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 55 (5) , 588-593
Management of aerosol generation during upper gastrointestinal endoscopy
In the highly contagious coronavirus disease 2019 pandemic, aerosol-generating procedures (AGPs) are associated with high-risk of transmission. Upper gastrointestinal endoscopy is a procedure with the potential to cause dissemination of bodily fluids. At present, there is no consensus that endoscopy is defined as an AGP. This review discusses the current evidence on this topic with additional management. Prevailing publications on coronavirus related to upper gastrointestinal endoscopy and aerosolization from the PubMed and Scopus databases were searched and reviewed. Comparative quantitative analyses showed a significant elevation of particle numbers, implying that aerosols were generated by upper gastrointestinal endoscopy. The associated source events have also been reported. To reduce the dispersion, certain protective measures have been developed. Endoscopic unit protocols are recommended for the concerned personnel. Therefore, upper gastrointestinal endoscopy should be classified as an AGP. Proper practices should be adopted by healthcare workers and patients.
- 24 August 2022
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 55 (5) , 588-593
Open AccessManagement of aerosol generation during upper gastrointestinal endoscopy
In the highly contagious coronavirus disease 2019 pandemic, aerosol-generating procedures (AGPs) are associated with high-risk of transmission. Upper gastrointestinal endoscopy is a procedure with the potential to cause dissemination of bodily fluids. At present, there is no consensus that endoscopy is defined as an AGP. This review discusses the current evidence on this topic with additional management. Prevailing publications on coronavirus related to upper gastrointestinal endoscopy and aerosolization from the PubMed and Scopus databases were searched and reviewed. Comparative quantitative analyses showed a significant elevation of particle numbers, implying that aerosols were generated by upper gastrointestinal endoscopy. The associated source events have also been reported. To reduce the dispersion, certain protective measures have been developed. Endoscopic unit protocols are recommended for the concerned personnel. Therefore, upper gastrointestinal endoscopy should be classified as an AGP. Proper practices should be adopted by healthcare workers and patients.